Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06944444 | A Phase I Clinical Study of SSS59 Monotherapy in Patients With Advanced Malignant Tumors | recruiting | Phase 1 | 154 | Shenyang Sunshine Pharmaceutical Co., LTD.INDUSTRY | 1 | Apr 29, 2025 | clinicaltrials |
| NCT05535413 | UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases | recruiting | Phase 1 / Phase 2 | 30 | Hunan Cancer HospitalOTHER | 1 | Apr 25, 2025 | clinicaltrials |
| NCT06188624 | Clinical Trial of TQB2922 for Injection in Patients With Advanced Cancers | recruiting | Phase 1 | 150 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
| NCT06669975 | A Study of AP402 in HER2-Positive Patients With Locally or Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 85 | AP Biosciences Inc.INDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
| NCT06907628 | A Trial of SHR-3792 Injection in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 150 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
| NCT06944457 | Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of MPD-1 in Patients With Advanced Solid Tumor | recruiting | Phase 1 | 24 | Pharosgen Co.,LtdINDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
| NCT03571568 | A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL | recruiting | Phase 1 / Phase 2 | 140 | BioInvent International ABINDUSTRY | 6 | Apr 24, 2025 | clinicaltrials |
| NCT06046495 | A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer | recruiting | Phase 1 | 81 | Avistone Biotechnology Co., Ltd.INDUSTRY | 1 | Apr 23, 2025 | clinicaltrials |
| NCT06297941 | Study of REM-422 in Patients With AML or Higher Risk MDS | recruiting | Phase 1 | 100 | Remix TherapeuticsINDUSTRY | 2 | Apr 23, 2025 | clinicaltrials |
| NCT06702995 | Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 / Phase 2 | 307 | Evopoint Biosciences Inc.INDUSTRY | 1 | Apr 20, 2025 | clinicaltrials |
| NCT05749432 | A Phase I Study of Hemay181 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 51 | Ganzhou Hemay Pharmaceutical Co., LtdINDUSTRY | 1 | Apr 18, 2025 | clinicaltrials |
| NCT06118788 | Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | recruiting | Phase 1 / Phase 2 | 24 | Guangzhou Bio-gene Technology Co., LtdINDUSTRY | 1 | Apr 17, 2025 | clinicaltrials |
| NCT06754930 | A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC | recruiting | Phase 1 / Phase 2 | 400 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Apr 17, 2025 | clinicaltrials |
| NCT04494503 | Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL | recruiting | Phase 1 / Phase 2 | 123 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Apr 16, 2025 | clinicaltrials |
| NCT05473624 | Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 153 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 15, 2025 | clinicaltrials |
| NCT06462365 | Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT) | recruiting | Phase 1 | 36 | Tr1X, Inc.INDUSTRY | 1 | Apr 15, 2025 | clinicaltrials |
| NCT06927349 | A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1301 in Advanced Solid Tumors. | recruiting | Phase 1 | 70 | Shandong Boan Biotechnology Co., LtdINDUSTRY | 1 | Apr 15, 2025 | clinicaltrials |
| NCT05423691 | Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs(TREG108) | recruiting | Phase 1 | 24 | Cellenkos, Inc.INDUSTRY | 1 | Apr 13, 2025 | clinicaltrials |
| NCT06094556 | An Open Phase I Clinical Trial of SHR-1826 for Injection in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 240 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Apr 13, 2025 | clinicaltrials |
| NCT06480110 | Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer | recruiting | Phase 1 / Phase 2 | 30 | Rigshospitalet, DenmarkOTHER | 1 | Apr 13, 2025 | clinicaltrials |
| NCT06926413 | A Study Evaluating the Effect of Aumolertinib on the Pharmacokinetics of Midazolam in Patients With NSCLC | recruiting | Phase 1 | 20 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 13, 2025 | clinicaltrials |
| NCT04215809 | Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL | recruiting | Phase 1 | 144 | Ascentage Pharma Group Inc.INDUSTRY | 2 | Apr 10, 2025 | clinicaltrials |
| NCT05588648 | Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma | recruiting | Phase 1 / Phase 2 | 48 | MedPacto, Inc.INDUSTRY | 2 | Apr 10, 2025 | clinicaltrials |
| NCT06431243 | A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 132 | Chengdu Zenitar Biomedical Technology Co., LtdINDUSTRY | 1 | Apr 10, 2025 | clinicaltrials |
| NCT06760364 | A Clinical Study of CHT102 in MSLN-Positive Advanced Pancreatic Cancer(CHAMPION) | recruiting | Phase 1 | 21 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT06096974 | Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS | recruiting | Phase 1 | 60 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 1 | Apr 9, 2025 | clinicaltrials |
| NCT06621563 | Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors(HS-20117) | recruiting | Phase 1 | 780 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Apr 9, 2025 | clinicaltrials |
| NCT06674265 | Safety and Efficacy of Systemic Allogenic NK Cells in R/R Neuroblastoma | recruiting | Phase 1 | 10 | Marzieh EbrahimiINDUSTRY | 1 | Apr 9, 2025 | clinicaltrials |
| NCT06710379 | A Study of ADRX-0405 in Subjects With Select Advanced Solid Tumors | recruiting | Phase 1 | 68 | Adcentrx TherapeuticsINDUSTRY | 1 | Apr 9, 2025 | clinicaltrials |
| NCT05544240 | Phase 1 Trial of SYNC-T - Immunotherapy for Patients With Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 20 | Williams Cancer FoundationOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT06914037 | A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies(COURAGE) | recruiting | Phase 1 | 24 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT05687747 | Single Centre Prospective Evaluation of 68Gallium-FAPI PET/MRI in Hepatocellular Carcinoma | recruiting | Phase 1 | 100 | National University Hospital, SingaporeOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT06911333 | AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors(AD1208) | recruiting | Phase 1 / Phase 2 | 36 | Avelos Therapeutics Inc.INDUSTRY | 1 | Apr 4, 2025 | clinicaltrials |
| NCT06911710 | The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors(CAR-T) | recruiting | Phase 1 / Phase 2 | 90 | Tianjin Medical University General HospitalOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT06446713 | PIRATES: Image-guided Hyper-fractioned Dose-escalation With Proton Therapy for Head and Neck Cancer(PIRATES) | recruiting | Phase 1 | 17 | University Medical Center GroningenOTHER | 1 | Apr 3, 2025 | clinicaltrials |
| NCT06760039 | Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL | recruiting | Phase 1 / Phase 2 | 112 | Sun Yat-sen UniversityOTHER | 1 | Apr 3, 2025 | clinicaltrials |
| NCT06903117 | Anti-CEA CAR-T for Advanced CEA-Positive Lung Carcinoma | recruiting | Phase 1 | 60 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Apr 3, 2025 | clinicaltrials |
| NCT06056362 | Comparison of Al18F-NOTA-LM3 With 68Ga-DOTATATE and 68Ga-NODAGA-LM3 PET/CT in Patients With Well-differentiated Neuroendocrine Tumors | recruiting | Phase 1 / Phase 2 | 80 | Peking Union Medical College HospitalOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT06484829 | Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 144 | Chengdu Zenitar Biomedical Technology Co., LtdINDUSTRY | 1 | Apr 2, 2025 | clinicaltrials |
| NCT06900647 | Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer(BOCIS) | recruiting | Phase 1 | 20 | Sun Yat-sen UniversityOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT05269316 | Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 61 | Impact Therapeutics, Inc.INDUSTRY | 4 | Apr 1, 2025 | clinicaltrials |
| NCT05477849 | A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 in Patients with Solid Tumors | recruiting | Phase 1 | 30 | Shanghai Virogin Biotech Co., Ltd.INDUSTRY | 1 | Apr 1, 2025 | clinicaltrials |
| NCT06811870 | A Phase II Single-Arm Clinical Study to Explore the Efficacy and Safety of Hyperbaric Oxygen in the Neoadjuvant Treatment of Breast Cancer Patients | recruiting | Phase 1 / Phase 2 | 161 | Guangdong Provincial People's HospitalOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT05460507 | Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment | recruiting | Phase 1 | 40 | Plus TherapeuticsINDUSTRY | 1 | Mar 30, 2025 | clinicaltrials |
| NCT05784688 | Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 140 | TiumBio Co., Ltd.INDUSTRY | 2 | Mar 30, 2025 | clinicaltrials |
| NCT06221553 | Safety and Efficacy of Loco-regional B7H3 IL-7Ra CAR T Cell in DIPG(CMD03DIPG) | recruiting | Phase 1 | 9 | Chulalongkorn UniversityOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT06594679 | A Study of Niraparib in Combination With Abemaciclib for Late Line Treatment of Ovarian Cancer (NICHOL TRIAL)(NICHOL) | recruiting | Phase 1 / Phase 2 | 73 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT01906385 | Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT) | recruiting | Phase 1 / Phase 2 | 55 | Plus TherapeuticsINDUSTRY | 1 | Mar 26, 2025 | clinicaltrials |
| NCT05473156 | A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies(APT-CUBE) | recruiting | Phase 1 / Phase 2 | 168 | AP Biosciences Inc.INDUSTRY | 1 | Mar 26, 2025 | clinicaltrials |
| NCT06716619 | A Phase I Trial of Tumor-Associated Lymph Node T-Cell Injection With Advanced Malignant Solid Tumors | recruiting | Phase 1 | 32 | Guangzhou FineImmune Biotechnology Co., LTD.INDUSTRY | 1 | Mar 26, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Apr 29, 2025source: clinicaltrials